Anil Aktas-Samur, PhD of Dana-Farber Cancer Institute (Boston, USA) presented her work on genomic features driving probability of progression in precursor conditions in myeloma.
Nizar Bahlis, MD of Calgary University (Canada) presented his data on the efficiency of Bcl-xL armored CAR T cells in eradicating MM cells.
Sara Gandolfi, MD of Helsinki University (Finland) presented her data on CRISPR screens with single-cell transcriptome readout revealing potential mechanisms of response to natural killer cell treatment in multiple myeloma.
Annamaria Gulla, MD of Dana-Farber Cancer Institute (Boston, USA) discussed her data showing that loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma. Annamaria Gulla is a IMS Exemplary Abstract Award recipient.
Suzanne Lentzsch, MD of Columbia University (New York, USA) discussed the efficacy of targeting GCK in RAS-mutant multiple myeloma cells.
Enrico Milan, PhD of University of Milano (Italy) presented data on FAM46C-Dependent tuning of endoplasmic reticulum capacity in multiple myeloma. Enrico Milan is a IMS Exemplary Abstract Award recipient
Maria Moscvin, MD of Brigham & Women Hospital (Boston, USA) presented data to support Targeting Free Light Chain Secretion via Botulinum Neurotoxin as a Novel Therapeutic Strategy in AL amyloidosis by Inducing a Terminal Unfolded Protein Response. Maria Moscvin is a IMS Exemplary Abstract Award recipient.
Eugenio Morelli, MD of Dana-Farber Cancer Institute (Boston, USA) reported his genome-wide CRISPR interference screen to identify novel lncRNA dependencies, including RNA Regulator of Lipogenesis (RROL). Eugenio Morelli is a IMS Exemplary Abstract Award recipient.
Cristina Panaroni, PhD of Mass General Hospital (Boston, USA) reported her data regarding metabolic reprogramming of multiple myeloma cells induced by bone marrow adipocytes.
Alexandra Poos, PhD of Heidelberg University (Germany) presented her data on single-cell multiomic analysis to identify regulatory programs in relapsed/refractory multiple myeloma.
Mehmet Samur, PhD of Dana-Farber Cancer Institute (Boston, USA) presented his data on monoallelic deletion of BCMA locus as a frequent feature in MM associated with increased genomic loss.
Antonio Solimando, MD of University of Bari (Italy) presented data on cell adhesion-regulated epithelial-mesenchymal-transition resulting in extramedullary multiple myeloma disease manifestation. Antonio Solimando is a IMS Exemplary Abstract Award recipient.
Rodger Tiedemann, MD of Princess Margaret Cancer Centre (Canada) reported that Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers.
Yu-Tzu Tai, PhD of Dana-Farber Cancer Institute (Boston, USA) presented data on the synergistic activity of BCMA-specific ADC MEDI2228 in combination with Daratumumab against myeloma cell survival by inducing IFN-driven innate immune responses and expression of CD38 and NKG2D ligands in tumor cells.